伊立替康联合贝伐单抗治疗铂类耐药复发性卵巢癌疗效观察

doi:10.3969/j.issn.1671-7171.2020.12.006

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of Irinotecan combined with bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. 【Methods】A total of 118 patients with platinum-resistant recurrent ovarian cancer treated in our hospital from Sep. 2016 to Sep. 2018 were randomly divided into the control group and the observation group with 59 cases in each group. The control group was treated with Irinotecan, while the observation group was treated with Irinotecan combined with bevacizumab. The short-term efficacy, serum tumor markers such as human epididymal secretory protein 4 (HE4), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), long-term efficacy and adverse reactions of the two groups were compared. 【Results】 After treatment, the objective remission rate (ORR) in the observation group was significantly higher than that in the control group (57.63% vs 37.29%, P<0.05). The levels of HE4,CA125, and CEA in both groups were lower than those before treatment, and those in the observation group were significantly lower than those in the control group (P<0.05). The total survival time (OS) and progression-free survival (PFS) of patients in the observation group were significantly longer than those in the control group (P<0.05). The incidence of hemoglobin decrease, renal function damage, alanine aminotransferase increase, central granulocyte decrease, thrombocytopenia, and peripheral neuritis in the two groups were compared (P>0.05). The incidence of grade 0 leukopenia in the observation group was significantly higher than that in the control group (P<0.05). The incidence of grade Ⅲ-Ⅳ diarrhea and nausea and vomiting in the observation group was significantly lower than that in the control group (P<0.05). 【Conclusion】Irinotecan combined with bevacizumab is effective in the treatment of platinum-resistant recurrent ovarian cancer. It can also improve PFS and OS in patients with platinum-resistant ovarian cancer, and the adverse reactions are tolerable. It is worthy of clinical application.

Key words： Ovarian Neoplasms/DT Antineoplastic Agents/TU Platinum Treatment Outcome

Received: 05 May 2019

PACS:

R737.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Zi-qin
	CHENG Xian-ying

Cite this article:

SUN Zi-qin,CHENG Xian-ying. Therapeutic Effect of Irinotecan Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(12): 1782-1785.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.12.006 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I12/1782

[1] PARP抑制剂治疗复发性卵巢癌专家共识[J].现代妇产科进展,2018,27(10):4-8.
[2] 张孟伟,秦亚光,王亚秋,等.铂类耐药复发转移性卵巢癌贝伐单抗联合白蛋白结合型紫杉醇治疗临床观察[J].中华肿瘤防治杂志,2016,23(5):331-334.
[3] Liu D,Ha C,Zhang X,et al.Molecular implication of ADAM-15 and 17 in intrauterine adhesions [J].Eur J Obstet Gynecol Reprod Biol,2013,170(1):264-269.
[4] 张淼慈,李萍,哈敏文.重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察[J].山东大学学报(医学版),2014,52(11):55-59.
[5] 苏安, 潘战和, 张靖,等. 伊立替康单药和联合沙利度胺治疗铂类耐药卵巢癌疗效比较观察[J].中华肿瘤防治杂志, 2009, 16(7):553-554.
[6] 刘更,易韬.畅贝伐单抗治疗卵巢癌的临床研究[J].四川解剖学杂志,2013,21(2):50-53.
[7] 丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展明[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[8] 陈杰,陈春婷,关慧,等.白蛋白结合型紫杉醇治疗紫杉类耐药的复发性卵巢癌的临床疗效[J].现代肿瘤医学,2016,24(10):3101-3104.
[9] 李丙森,孙夷平,刘虎,等.白蛋白结合型紫杉醇联合贝伐单抗治疗中老年复发转移性卵巢癌的疗效及对患者生存质量的影响[J].中国老年学杂志,2018,38(10):59-61.
[10] 陈曦,诸一鸣,张平,等.贝伐单抗联合TP方案治疗铂类化疗复发卵巢癌的临床疗效及安全性分析[J].中国生化药物杂志,2017,37(6):366-368.
[11] 张洁.抗血管生成药物联合化疗在复发性卵巢癌治疗中的研究进展[J].国际妇产科学杂志,2016,43(1):70-74.
[12] Pujade-Lauraine E, Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:The AURELIA open-label randomized phase Ⅲ trial [J].J Clin Oncol,2014,32(13):1302-1308.
[13] 康马飞, 卜庆, 刘瑛,等. 伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研究[J].中国全科医学, 2011, 14(33):3859-3860.
[14] 张庆松,李燕华.贝伐单抗在卵巢癌中的应用进展[J].肿瘤学杂志,2016,22(4):310-315.
[15] 阮冠宇,孙蓬明,林小梅.贝伐单抗联合化疗治疗卵巢癌有效性及安全性分析[J].中国妇产科临床杂志,2016,17(4):323-327.
[16] G siorowska E, Michalak M, Warcho W, et al. Clinical application of HE4 and CA125 in ovarian cancer type Ⅰ and type Ⅱ detection and differential diagnosis[J].Ginekol Pol,2015, 86(2):88-93.
[17] 姜靖,邓晓阳,胡晓蕙.CA125、CA199和CEA联合检测在卵巢癌诊断中的临床意义[J].中国实验诊断学,2014,18(7):1145-1148.
[18] 汤建新.人附睾分泌蛋白联合糖类抗原125在卵巢癌早期诊断中的研究进展[J].中国医刊,2014,49(12):22-24.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(9): 1405-1406.